Dr. Camillo Ricordi, MD is the Stacy Joy Goodman Professor of Surgery, Distinguished Professor of Medicine, and Professor of Biomedical Engineering, Microbiology, and Immunology at the University of Miami (UM), Florida, where he serves as Director of the Diabetes Research Institute (DRI)  and the Cell Transplant Center. Since 1993, Dr. Ricordi has been serving as Head of the NIH-funded current Good Manufacturing Practices (cGMP) Human Cell Processing Facility for the manufacturing of advanced human cell and other biologic products, for research and clinical applications at UM, in the US, and worldwide.

Acknowledged by his peers as one of the world's leading scientists in diabetes’ cure-focused research, cell transplantation, and regenerative medicine, Dr. Ricordi is well-known for inventing the machine that made it possible to isolate large numbers of islet cells (insulin-producing cells) from the human pancreas and for performing the first series of successful clinical islet allotransplants that reversed diabetes after the implantation of donor-purified islets into the liver of recipients with diabetes. The procedure is now used by laboratories performing clinical islet transplants worldwide. In 2017, the first NIH-funded FDA Phase 3 multicenter trial was successfully completed by the NIH Clinical Islet Transplantation Consortium, chaired by Dr. Ricordi for over a decade. He has also developed highly innovative strategies with the objective to transplant cells and organs without the continuous requirement for anti-rejection drugs and for the reversal of autoimmune disease conditions. Dr. Ricordi’s research interests include the definition of anti-inflammatory nutrition, protective substances, and regenerative medicine strategies to prevent or treat chronic degenerative disease conditions, and to prolong healthy lifespan (Healthspan).

Dr. Ricordi has received numerous honors and awards, including the 2001 Nessim Habif World Prize in Surgery (University of Geneva) for developing a technology that significantly contributed to the advancement of a surgical field. In 2002, he was awarded the Outstanding Scientific Achievement Award by the American Diabetes Association. In 2009, Dr. Ricordi was Knighted by the President of the Republic of Italy in the highest Order of the Republic (the Order of Merit) with the Knighthood decoration of Cavaliere Ufficiale. In 2018, Dr. Ricordi was inducted into the National Academy of Inventors for contributing outstanding inventions that have made a tangible impact on quality of life, economic development, and welfare of society. From 2019 to 2022, Dr. Ricordi was appointed to the Supreme Council of Health (Consiglio Superiore di Sanita) by the Ministry of Health of Italy.

Dr. Ricordi is currently serving as Editor-in-Chief of ERMPS.

Dr. Ricordi also serves as President of the Board of the Mediterranean Institute of Transplantation and Advanced Therapies (ISMETT).

Dr. Ricordi was Founding President of The Cure Alliance  and Chairman of the Diabetes Research Institute Federation, coordinating and promoting cure-focused research at over 24 leading institutions worldwide.

Dr. Ricordi has achieved an h-index of 109, has been awarded 27 patents, and has contributed to more than 1,170 publications that received over 52,000 citations.